SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about analyst meet

27 May 2025 Evaluate
Akums Drugs and Pharmaceuticals has informed that pursuant to regulation 30 read with Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals will be interacting with the Analysts / Investors, details of the meetings are enclosed.

The above information is a part of company’s filings submitted to BSE.

Akums Drugs & Pharma Share Price

653.50 2.90 (0.45%)
08-Jul-2026 13:54 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1883.00
Dr. Reddys Labs. 1348.50
Cipla 1436.90
Zydus Lifesciences 1160.90
Lupin 2478.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: